UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

_______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~May 923, 2012

_______________

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

_______________

DELAWARE	033-20897-D	91-2099117
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

22118 20th Avenue S.E., Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

_______________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 15.0107 Submission ~~Entry~~of ~~into~~Matters to a ~~Material~~Vote ~~Definitive~~of ~~Agreement~~Security Holders.

OnThe ~~April~~2012 9,Annual ~~2012,~~Meeting of the Stockholders of Helix BioMedix, Inc. (the “Company”) ~~entered~~was ~~into~~held aon ~~Third Amendment (the “Amendment”) with Camden Street Partners~~May 23, ~~LLC (“Camden”) and NuGlow Cosmaceuticals~~2012, ~~LLC~~at ~~(“NuGlow LLC”), pursuant to~~ which the ~~parties~~following ~~agreed~~matters towere ~~amend~~approved ~~that certain Amended and Restated Operating Agreement of NuGlow Cosmaceuticals, LLC dated~~ as of July 1, 2010, as amended (the “NuGlow LLC Operating Agreement”), to provide for the allocation and distribution of $27,000 and $63,000 in additional capital contributions in NuGlow LLC contemporaneously made by the Company and Camden, respectively, prior to other allocations or distributions thereunder.follows:

The election of the following Class III directors to serve until the 2015 Annual Meeting of Stockholders or until each such director’s successor is elected and qualified:

Nominee	For	Withheld	Broker Non-Votes
R. Stephen Beatty	33,143,658	275,270	6,996,500
John F. Clifford	33,208,734	210,194	6,996,500
Lawrence Blake Jones	33,295,958	122,970	6,996,500

The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012:

For		Against		Abstain		Broker Non-Votes
40,054,127		348,039		13,262		0

These are the final voting results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		HELIX BIOMEDIX, INC.
Dated: April 12, 2012	By:	/s/ R. Stephen Beatty
Dated: May 24, 2012	By:	/s/ R. Stephen Beatty
		R. Stephen Beatty
		President and Chief Executive Officer

Filing Compare · HELIX BIOMEDIX INC